1
|
Mascaro M, D'Ambrosio L, Lazzari E, Almoguera B, Swafiri ST, Zanchetta ME, Meroni G. A unique missense mutation in the RING domain impairs MID1 E3 ubiquitin ligase activity and localisation and is associated with uncommon Opitz Syndrome-like signs. Biochim Biophys Acta Mol Basis Dis 2024; 1870:167126. [PMID: 38508475 DOI: 10.1016/j.bbadis.2024.167126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 03/14/2024] [Accepted: 03/15/2024] [Indexed: 03/22/2024]
Affiliation(s)
- Martina Mascaro
- Department of Life Science, University of Trieste, Trieste 34127, Italy
| | - Luigi D'Ambrosio
- Department of Life Science, University of Trieste, Trieste 34127, Italy
| | - Elisa Lazzari
- Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste 34137, Italy
| | - Berta Almoguera
- Department of Genetics and Genomics Fundación Jiménez Díaz University Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid 28040, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Spain
| | - Saoud Tahsin Swafiri
- Department of Genetics and Genomics Fundación Jiménez Díaz University Hospital, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid 28040, Spain; Center for Biomedical Network Research on Rare Diseases (CIBERER), Spain
| | - Melania Eva Zanchetta
- Institute for Maternal and Child Health - IRCCS Burlo Garofolo, Trieste 34137, Italy.
| | - Germana Meroni
- Department of Life Science, University of Trieste, Trieste 34127, Italy.
| |
Collapse
|
2
|
Dalfino G, Sileo G, Ronchi A, Lazzari E, Castelnuovo P, Turri Zanoni M. Lateral Orbitotomy Cryo-Assisted Removal of Orbital Cavernous Hemangiomas: Case Report and Technical Hints. World Neurosurg 2023; 178:69. [PMID: 37453728 DOI: 10.1016/j.wneu.2023.07.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Revised: 07/05/2023] [Accepted: 07/06/2023] [Indexed: 07/18/2023]
Abstract
Orbital cavernous hemangiomas are the most common adult benign vascular orbital neoformation, representing 5%-15% of all orbital masses, and may involve the extraconal or intraconal space.1 According to the International Society for the Study of Vascular Anomalies, orbital cavernous hemangiomas should be classified as low-flow nondistensible venous malformations and are characterized by slow growth, generally 0.2 cm3/year.2,3 For these characteristics, complete surgical resection is necessary for symptomatic patients or in case of significant volumetric increase in its size.4Video 1 demonstrates the cryo-assisted removal of an intraconal orbital hemangioma (22 × 26 mm) located in the superior-lateral aspect of the right orbit in a 55-year-old woman. The patient presented with right exophthalmos and diplopia on right lateral gaze. The lesion was completely removed using a right lateral orbitotomy combined with a superior eyelid endoscopic-assisted approach. Intraoperative neuronavigation was used to correctly identify the location of the orbital hemangioma. Exophthalmos resolved postoperatively, without any cosmetic sequelae or visual impairment. Magnetic resonance imaging performed 8 months after surgery demonstrated excellent surgical outcomes, with complete resolution of the exophthalmos and without evidence of persistence of disease. A multidisciplinary approach, involving different specialists familiar with orbital anatomy and physiology, is fundamental in the management of these rare orbital pathologies.
Collapse
Affiliation(s)
- Gianluca Dalfino
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
| | - Giorgio Sileo
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Andrea Ronchi
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Elisa Lazzari
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Paolo Castelnuovo
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; Head and Neck Surgery & Forensic Dissection Research Center, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| | - Mario Turri Zanoni
- Division of Otorhinolaryngology, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy; Head and Neck Surgery & Forensic Dissection Research Center, Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy
| |
Collapse
|
3
|
Platonova N, Lazzari E, Colombo M, Falleni M, Tosi D, Giannandrea D, Citro V, Casati L, Ronchetti D, Bolli N, Neri A, Torricelli F, Crews LA, Jamieson CHM, Chiaramonte R. The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma. Int J Mol Sci 2023; 24:14558. [PMID: 37834003 PMCID: PMC10572399 DOI: 10.3390/ijms241914558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 09/03/2023] [Accepted: 09/20/2023] [Indexed: 10/15/2023] Open
Abstract
The NOTCH ligands JAG1 and JAG2 have been correlated in vitro with multiple myeloma (MM) cell proliferation, drug resistance, self-renewal and a pathological crosstalk with the tumor microenvironment resulting in angiogenesis and osteoclastogenesis. These findings suggest that a therapeutic approach targeting JAG ligands might be helpful for the care of MM patients and lead us to explore the role of JAG1 and JAG2 in a MM in vivo model and primary patient samples. JAG1 and JAG2 protein expression represents a common feature in MM cell lines; therefore, we assessed their function through JAG1/2 conditional silencing in a MM xenograft model. We observed that JAG1 and JAG2 showed potential as therapeutic targets in MM, as their silencing resulted in a reduction in the tumor burden. Moreover, JAG1 and JAG2 protein expression in MM patients was positively correlated with the presence of MM cells in patients' bone marrow biopsies. Finally, taking advantage of the Multiple Myeloma Research Foundation (MMRF) CoMMpass global dataset, we showed that JAG2 gene expression level was a predictive biomarker associated with patients' overall survival and progression-free survival, independently from other main molecular or clinical features. Overall, these results strengthened the rationale for the development of a JAG1/2-tailored approach and the use of JAG2 as a predictive biomarker in MM.
Collapse
Affiliation(s)
- Natalia Platonova
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| | - Elisa Lazzari
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, La Jolla, CA 92093, USA; (L.A.C.); (C.H.M.J.)
- UC San Diego Sanford, Stem Cell Institute, La Jolla, CA 92037, USA
| | - Michela Colombo
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| | - Monica Falleni
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
- Unit of Pathology A.O. San Paolo, Via A. Di Rudinì 8, 20142 Milan, Italy
| | - Delfina Tosi
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
- Unit of Pathology A.O. San Paolo, Via A. Di Rudinì 8, 20142 Milan, Italy
| | - Domenica Giannandrea
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| | - Valentina Citro
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| | - Lavinia Casati
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| | - Domenica Ronchetti
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; (D.R.); (N.B.)
| | - Niccolò Bolli
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, 20122 Milan, Italy; (D.R.); (N.B.)
- Hematology, Fondazione Cà Granda IRCCS Policlinico, 20122 Milan, Italy
| | - Antonino Neri
- Scientific Directorate, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;
| | - Federica Torricelli
- Laboratory of Translational Research, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy;
| | - Leslie A. Crews
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, La Jolla, CA 92093, USA; (L.A.C.); (C.H.M.J.)
| | - Catriona H. M. Jamieson
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, La Jolla, CA 92093, USA; (L.A.C.); (C.H.M.J.)
- UC San Diego Sanford, Stem Cell Institute, La Jolla, CA 92037, USA
| | - Raffaella Chiaramonte
- Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy; (N.P.); (E.L.); (M.C.); (M.F.); (D.T.); (D.G.); (V.C.); (L.C.)
| |
Collapse
|
4
|
Avataneo C, Petriglieri JR, Capella S, Tomatis M, Luiso M, Marangoni G, Lazzari E, Tinazzi S, Lasagna M, De Luca DA, Bergamini M, Belluso E, Turci F. Chrysotile asbestos migration in air from contaminated water: An experimental simulation. J Hazard Mater 2022; 424:127528. [PMID: 34736189 DOI: 10.1016/j.jhazmat.2021.127528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 10/13/2021] [Accepted: 10/14/2021] [Indexed: 06/13/2023]
Abstract
In Naturally Occurring Asbestos (NOA) rich areas, water flows through asbestos bearing rocks and soils and generates waterborne fibres that may migrate in air and become a risk for humans. Research on the migration and dispersion after water vaporisation has been so far only marginally evaluated. This study investigates the migration in air of asbestos from a set of suspensions contaminated by chrysotile from Balangero (Italy), under controlled laboratory conditions. We evaluated i) the morphological modifications that might occur to chrysotile during migration from water to air, and ii) the amount of airborne chrysotile mobilised from standardised suspensions. Morphological alteration of asbestos fibres occurred during water-air migration and impacted on the analytical response of electron microscopy. Waterborne asbestos concentration higher than 40 ∙ 106 f/L generates in air concentration higher than 1 fibre per litre [f/L], the alarm threshold limit set by World Health Organization for airborne asbestos. A possible correlation between the waterborne fibre concentration as mass or number of fibres per volume unit [μg/L or f/L] was observed.
Collapse
Affiliation(s)
- Chiara Avataneo
- Department of Earth Sciences, University of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy; "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy
| | - Jasmine R Petriglieri
- "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy; Department of Chemistry, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy
| | - Silvana Capella
- Department of Earth Sciences, University of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy; "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy
| | - Maura Tomatis
- "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy; Department of Chemistry, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy
| | - Mariagrazia Luiso
- RSA Srl, Società per il Risanamento e lo Sviluppo Ambientale dell'ex miniera di amianto di Balangero e Corio, Via Cave 24, I-10070 Balangero, TO, Italy
| | - Giuliana Marangoni
- RSA Srl, Società per il Risanamento e lo Sviluppo Ambientale dell'ex miniera di amianto di Balangero e Corio, Via Cave 24, I-10070 Balangero, TO, Italy
| | - Elisa Lazzari
- RSA Srl, Società per il Risanamento e lo Sviluppo Ambientale dell'ex miniera di amianto di Balangero e Corio, Via Cave 24, I-10070 Balangero, TO, Italy
| | - Silvio Tinazzi
- Microanalitica Srl, Via Reano 21/8, I-10098 Rivoli, TO, Italy
| | - Manuela Lasagna
- Department of Earth Sciences, University of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy
| | - Domenico A De Luca
- Department of Earth Sciences, University of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy
| | - Massimo Bergamini
- RSA Srl, Società per il Risanamento e lo Sviluppo Ambientale dell'ex miniera di amianto di Balangero e Corio, Via Cave 24, I-10070 Balangero, TO, Italy
| | - Elena Belluso
- Department of Earth Sciences, University of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy; "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy; Geosciences and Earth Resources (IGG) of the National Research Council of Italy (CNR), Operational Unit of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy
| | - Francesco Turci
- "G. Scansetti" Interdepartmental Center for Studies on Asbestos and Other Toxic Particulates, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy; Department of Chemistry, University of Turin, Via Pietro Giuria 7, I-10125 Turin, Italy; Geosciences and Earth Resources (IGG) of the National Research Council of Italy (CNR), Operational Unit of Turin, Via Valperga Caluso 35, I-10125 Turin, Italy.
| |
Collapse
|
5
|
Oud TAM, Lazzari E, Gijsbers HJH, Gobbo M, Nollet F, Brehm MA. Effectiveness of 3D-printed orthoses for traumatic and chronic hand conditions: A scoping review. PLoS One 2021; 16:e0260271. [PMID: 34793566 PMCID: PMC8601455 DOI: 10.1371/journal.pone.0260271] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 11/06/2021] [Indexed: 11/26/2022] Open
Abstract
Background In the field of orthotics, the use of three-dimensional (3D) technology as an alternative to the conventional production process of orthoses is growing. Purpose This scoping review aimed to systematically map and summarize studies assessing the effectiveness of 3D-printed orthoses for traumatic and chronic hand conditions, and to identify knowledge gaps. Methods The Cochrane Library, PubMed, EMBASE, CINAHL, Web of Science, IEEE, and PEDro were searched for studies of any type of 3D-printed orthoses for traumatic and chronic hand conditions. Any outcome related to the effectiveness of 3D-printed orthoses was considered. Two reviewers selected eligible studies, charted data on study characteristics by impairment type, and critically appraised the studies, except for case reports/series. Results Seventeen studies were included: four randomized controlled trials, four uncontrolled trials, four case series and five case reports. Only three studies had a sample size >20. Impairments described were forearm fractures (n = 5), spasticity (n = 5), muscle weakness (n = 4), joint contractures (n = 2) and pain (n = 1). Four poor to fair quality studies on forearm fractures supported the effectiveness of 3D-printed orthoses on hand function, functionality, and satisfaction. One good quality study on spasticity demonstrated the effectiveness of 3D-printed orthoses on hand function. One poor quality pain study reported limited positive effects on satisfaction. Studies on muscle weakness and joint contractures showed no benefits. Conclusion Current literature addressing the effectiveness of 3D-printed orthoses for traumatic and chronic hand conditions consists primarily of small and poor methodological quality studies. There is a need for well-designed controlled trials including patient-related outcomes, production time and cost analyses.
Collapse
Affiliation(s)
- T. A. M. Oud
- Amsterdam UMC, University of Amsterdam, Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam, The Netherlands
- * E-mail:
| | - E. Lazzari
- Laboratory of Clinical Integrative Physiology, University of Brescia, Brescia, Italy
| | - H. J. H. Gijsbers
- Amsterdam UMC, University of Amsterdam, Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam, The Netherlands
| | - M. Gobbo
- Laboratory of Clinical Integrative Physiology, University of Brescia, Brescia, Italy
- Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy
| | - F. Nollet
- Amsterdam UMC, University of Amsterdam, Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam, The Netherlands
| | - M. A. Brehm
- Amsterdam UMC, University of Amsterdam, Rehabilitation Medicine, Amsterdam Movement Sciences, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Ramalingam P, Poulos MG, Gutkin MC, Katsnelson L, Freire AG, Lazzari E, Butler JM. Endothelial mTOR maintains hematopoiesis during aging. J Exp Med 2021; 217:151661. [PMID: 32289154 PMCID: PMC7971143 DOI: 10.1084/jem.20191212] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2019] [Revised: 12/18/2019] [Accepted: 03/13/2020] [Indexed: 12/24/2022] Open
Abstract
Aging leads to a decline in hematopoietic stem and progenitor cell (HSPC) function. We recently discovered that aging of bone marrow endothelial cells (BMECs) leads to an altered crosstalk between the BMEC niche and HSPCs, which instructs young HSPCs to behave as aged HSPCs. Here, we demonstrate aging leads to a decrease in mTOR signaling within BMECs that potentially underlies the age-related impairment of their niche activity. Our findings reveal that pharmacological inhibition of mTOR using Rapamycin has deleterious effects on hematopoiesis. To formally determine whether endothelial-specific inhibition of mTOR can influence hematopoietic aging, we conditionally deleted mTOR in ECs (mTOR(ECKO)) of young mice and observed that their HSPCs displayed attributes of an aged hematopoietic system. Transcriptional profiling of HSPCs from mTOR(ECKO) mice revealed that their transcriptome resembled aged HSPCs. Notably, during serial transplantations, exposure of wild-type HSPCs to an mTOR(ECKO) microenvironment was sufficient to recapitulate aging-associated phenotypes, confirming the instructive role of EC-derived signals in governing HSPC aging.
Collapse
Affiliation(s)
- Pradeep Ramalingam
- Department of Medicine, Division of Regenerative Medicine, Weill Cornell Medical College, New York, NY
| | - Michael G Poulos
- Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
| | - Michael C Gutkin
- Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
| | - Lizabeth Katsnelson
- Department of Medicine, Division of Regenerative Medicine, Weill Cornell Medical College, New York, NY
| | - Ana G Freire
- Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
| | - Elisa Lazzari
- Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ
| | - Jason M Butler
- Department of Medicine, Division of Regenerative Medicine, Weill Cornell Medical College, New York, NY.,Center for Discovery and Innovation, Hackensack University Medical Center, Nutley, NJ.,Molecular Oncology Program, Georgetown University, Washington, DC
| |
Collapse
|
7
|
Mondala PK, Vora AA, Zhou T, Lazzari E, Ladel L, Luo X, Kim Y, Costello C, MacLeod AR, Jamieson CHM, Crews LA. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption. Cell Stem Cell 2021; 28:623-636.e9. [PMID: 33476575 DOI: 10.1016/j.stem.2020.12.017] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Revised: 10/22/2020] [Accepted: 12/21/2020] [Indexed: 12/22/2022]
Abstract
In multiple myeloma, inflammatory and anti-viral pathways promote disease progression and cancer stem cell generation. Using diverse pre-clinical models, we investigated the role of interferon regulatory factor 4 (IRF4) in myeloma progenitor regeneration. In a patient-derived xenograft model that recapitulates IRF4 pathway activation in human myeloma, we test the effects of IRF4 antisense oligonucleotides (ASOs) and identify a lead agent for clinical development (ION251). IRF4 overexpression expands myeloma progenitors, while IRF4 ASOs impair myeloma cell survival and reduce IRF4 and c-MYC expression. IRF4 ASO monotherapy impedes tumor formation and myeloma dissemination in xenograft models, improving animal survival. Moreover, IRF4 ASOs eradicate myeloma progenitors and malignant plasma cells while sparing normal human hematopoietic stem cell development. Mechanistically, IRF4 inhibition disrupts cell cycle progression, downregulates stem cell and cell adhesion transcript expression, and promotes sensitivity to myeloma drugs. These findings will enable rapid clinical development of selective IRF4 inhibitors to prevent myeloma progenitor-driven relapse.
Collapse
Affiliation(s)
- Phoebe K Mondala
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
| | - Ashni A Vora
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
| | | | - Elisa Lazzari
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
| | - Luisa Ladel
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
| | - Xiaolin Luo
- Ionis Pharmaceuticals, Carlsbad, CA 92008, USA
| | | | - Caitlin Costello
- Moores Cancer Center at University of California, San Diego, La Jolla, CA 92093, USA; Division of Blood and Marrow Transplantation, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
| | | | - Catriona H M Jamieson
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Moores Cancer Center at University of California, San Diego, La Jolla, CA 92093, USA.
| | - Leslie A Crews
- Division of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; Moores Cancer Center at University of California, San Diego, La Jolla, CA 92093, USA.
| |
Collapse
|
8
|
Colombo M, Garavelli S, Mazzola M, Platonova N, Giannandrea D, Colella R, Apicella L, Lancellotti M, Lesma E, Ancona S, Palano MT, Barbieri M, Taiana E, Lazzari E, Basile A, Turrini M, Pistocchi A, Neri A, Chiaramonte R. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica 2019; 105:1925-1936. [PMID: 31582544 PMCID: PMC7327642 DOI: 10.3324/haematol.2019.221077] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2019] [Accepted: 09/26/2019] [Indexed: 12/12/2022] Open
Abstract
Multiple myeloma is still incurable due to an intrinsic aggressiveness or, more frequently, to the interactions of malignant plasma cells with the bone marrow (BM) microenvironment. Myeloma cells educate BM cells to support neoplastic cell growth, survival, acquisition of drug resistance resulting in disease relapse. Myeloma microenvironment is characterized by Notch signaling hyperactivation due to the increased expression of Notch1 and 2 and the ligands Jagged1 and 2 in tumor cells. Notch activation influences myeloma cell biology and promotes the reprogramming of BM stromal cells. In this work we demonstrate, in vitro, ex vivo and by using a zebrafish multiple myeloma model, that Jagged inhibition causes a decrease in both myeloma-intrinsic and stromal cell-induced resistance to currently used drugs, i.e. bortezomib, lenalidomide and melphalan. The molecular mechanism of drug resistance involves the chemokine system CXCR4/SDF1α. Myeloma cell-derived Jagged ligands trigger Notch activity in BM stromal cells. These, in turn, secrete higher levels of SDF1α in the BM microenvironment increasing CXCR4 activation in myeloma cells, which is further potentiated by the concomitant increased expression of this receptor induced by Notch activation. Consistently with the augmented pharmacological resistance, SDF1α boosts the expression of BCL2, Survivin and ABCC1. These results indicate that a Jagged-tailored approach may contribute to disrupting the pharmacological resistance due to intrinsic myeloma cell features or to the pathological interplay with BM stromal cells and, conceivably, improve patients' response to standard-of-care therapies.
Collapse
Affiliation(s)
- Michela Colombo
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | - Silvia Garavelli
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | - Mara Mazzola
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano
| | - Natalia Platonova
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | | | - Raffaella Colella
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | - Luana Apicella
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | | | - Elena Lesma
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | - Silvia Ancona
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | | | - Marzia Barbieri
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano.,Hematology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
| | - Elisa Taiana
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano.,Hematology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
| | - Elisa Lazzari
- Department of Health Sciences, Università degli Studi di Milano, Milano
| | - Andrea Basile
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano
| | - Mauro Turrini
- Department of Hematology, Division of Medicine, Valduce Hospital, Como, Italy
| | - Anna Pistocchi
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano
| | - Antonino Neri
- Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milano.,Hematology, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milano
| | | |
Collapse
|
9
|
Jiang Q, Isquith J, Zipeto MA, Diep RH, Pham J, Delos Santos N, Reynoso E, Chau J, Leu H, Lazzari E, Melese E, Ma W, Fang R, Minden M, Morris S, Ren B, Pineda G, Holm F, Jamieson C. Hyper-Editing of Cell-Cycle Regulatory and Tumor Suppressor RNA Promotes Malignant Progenitor Propagation. Cancer Cell 2019; 35:81-94.e7. [PMID: 30612940 PMCID: PMC6333511 DOI: 10.1016/j.ccell.2018.11.017] [Citation(s) in RCA: 59] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Revised: 10/20/2018] [Accepted: 11/26/2018] [Indexed: 12/26/2022]
Abstract
Adenosine deaminase associated with RNA1 (ADAR1) deregulation contributes to therapeutic resistance in many malignancies. Here we show that ADAR1-induced hyper-editing in normal human hematopoietic progenitors impairs miR-26a maturation, which represses CDKN1A expression indirectly via EZH2, thereby accelerating cell-cycle transit. However, in blast crisis chronic myeloid leukemia progenitors, loss of EZH2 expression and increased CDKN1A oppose cell-cycle transit. Moreover, A-to-I editing of both the MDM2 regulatory microRNA and its binding site within the 3' UTR region stabilizes MDM2 transcripts, thereby enhancing blast crisis progenitor propagation. These data reveal a dual mechanism governing malignant transformation of progenitors that is predicated on hyper-editing of cell-cycle-regulatory miRNAs and the 3' UTR binding site of tumor suppressor miRNAs.
Collapse
Affiliation(s)
- Qingfei Jiang
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
| | - Jane Isquith
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Maria Anna Zipeto
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Raymond H Diep
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Jessica Pham
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Nathan Delos Santos
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Eduardo Reynoso
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Julisia Chau
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Heather Leu
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Elisa Lazzari
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Etienne Melese
- Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
| | - Wenxue Ma
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Rongxin Fang
- Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA; Bioinformatics and Systems Biology Graduate Program, University of California, San Diego, La Jolla, CA 92093, USA
| | - Mark Minden
- Princess Margaret Hospital, Toronto, ON M5T 2M9, Canada
| | - Sheldon Morris
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA
| | - Bing Ren
- Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA; Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA, USA; Department of Cellular and Molecular Medicine, Institute of Genomic Medicine, and Moores Cancer Center, University of California at San Diego, La Jolla, CA 92093, USA
| | - Gabriel Pineda
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA; Department of Health Sciences, School of Health and Human Services, National University, San Diego, CA, USA
| | - Frida Holm
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA
| | - Catriona Jamieson
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
| |
Collapse
|
10
|
Crews LA, Lazzari E, Mondala PK, Santos ND, Miller A, Pineda G, Jiang Q, Ganesan AP, Wu C, Costello C, Minden M, Chiaramonte R, Stewart AK, Jamieson CHM. Abstract 4437: Down-modulation of ADAR1-mediated GLI1 editing alters extracellular and immune response genes in multiple myeloma. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-4437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Representing 10% of hematologic malignancies, multiple myeloma (MM) is typified by clonal plasma cell proliferation in the bone marrow (BM) and may progress to therapy-resistant plasma cell leukemia (PCL). Despite many novel therapies, relapse rates remain high as a result of malignant regeneration (self-renewal) of MM cells in inflammatory microenvironments. In addition to recurrent DNA mutations and epigenetic deregulation, inflammatory cytokine-responsive adenosine deaminase associated with RNA (ADAR1)-mediated adenosine to inosine (A-to-I) RNA editing has emerged as a key driver of cancer relapse and progression. In MM, copy number amplification of chromosome 1q21, which contains both ADAR1 and interleukin-6 receptor (IL-6R) gene loci, portends a poor prognosis. Thus, we hypothesized that ADAR1 copy number amplification combined with inflammatory cytokine activation of ADAR1 stimulates malignant regeneration of MM and therapeutic resistance.
Methods and Results: Analysis of MMRF CoMMpass RNA sequencing (RNA-seq) data revealed that high ADAR1 expression (n=162 patients) correlated with significantly reduced progression-free and overall survival compared with a low ADAR1 subset (n=159 patients). In contrast to lentiviral ADAR1 shRNA knockdown and overexpression of an editase defective ADAR1 mutant (ADAR1E912A), lentiviral wild-type ADAR1 overexpression enhanced editing of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist. Editing of GLI1 transcripts enhanced GLI transcriptional activity in luciferase reporter assays, and promoted lenalidomide resistance in vitro. Finally, lentiviral shRNA ADAR1 knockdown reduced regeneration of high-risk MM in humanized serial transplantation mouse models, indicative of reduced malignant self-renewal capacity. Whole-transcriptome RNA-sequencing of primary samples after lentiviral shRNA knockdown of ADAR1 revealed specific modulation of extracellular and immune response genes, while overexpression of wild-type versus edited GLI1 elicited distinct gene expression changes in human myeloma cells analyzed using NanoString nCounter assays. These data demonstrate that ADAR1 promotes malignant self-renewal of MM and, if selectively inhibited, may prevent progression and relapse through modulation of extracellular and immune response genes.
Conclusions: Deregulated RNA editing, driven by aberrant ADAR1 activation, represents a unique source of transcriptomic and proteomic diversity, resulting in self-renewal of MM cells in inflammatory microenvironments. In summary, both genetic (1q21 amplification) and microenvironmental factors (inflammatory cytokines, IMiDs) combine to drive GLI1-dependent malignant regeneration in MM. Thus, ADAR1 represents both a vital prognostic biomarker and therapeutic target in MM.
Citation Format: Leslie A. Crews, Elisa Lazzari, Phoebe K. Mondala, Nathaniel Delos Santos, Amber Miller, Gabriel Pineda, Qingfei Jiang, Anusha-Preethi Ganesan, Christina Wu, Caitlin Costello, Mark Minden, Raffaella Chiaramonte, A. Keith Stewart, Catriona H. M. Jamieson. Down-modulation of ADAR1-mediated GLI1 editing alters extracellular and immune response genes in multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4437.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Mark Minden
- 3Princess Margaret Hospital, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|
11
|
Lazzari E, Mondala PK, Santos ND, Miller AC, Pineda G, Jiang Q, Leu H, Ali SA, Ganesan AP, Wu CN, Costello C, Minden M, Chiaramonte R, Stewart AK, Crews LA, Jamieson CHM. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Nat Commun 2017; 8:1922. [PMID: 29203771 PMCID: PMC5715072 DOI: 10.1038/s41467-017-01890-w] [Citation(s) in RCA: 80] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Accepted: 10/24/2017] [Indexed: 12/12/2022] Open
Abstract
Despite novel therapies, relapse of multiple myeloma (MM) is virtually inevitable. Amplification of chromosome 1q, which harbors the inflammation-responsive RNA editase adenosine deaminase acting on RNA (ADAR)1 gene, occurs in 30–50% of MM patients and portends a poor prognosis. Since adenosine-to-inosine RNA editing has recently emerged as a driver of cancer progression, genomic amplification combined with inflammatory cytokine activation of ADAR1 could stimulate MM progression and therapeutic resistance. Here, we report that high ADAR1 RNA expression correlates with reduced patient survival rates in the MMRF CoMMpass data set. Expression of wild-type, but not mutant, ADAR1 enhances Alu-dependent editing and transcriptional activity of GLI1, a Hedgehog (Hh) pathway transcriptional activator and self-renewal agonist, and promotes immunomodulatory drug resistance in vitro. Finally, ADAR1 knockdown reduces regeneration of high-risk MM in serially transplantable patient-derived xenografts. These data demonstrate that ADAR1 promotes malignant regeneration of MM and if selectively inhibited may obviate progression and relapse. The treatment of multiple myeloma is challenging due to high relapse rates. Here the authors show that expression of ADAR1 correlates with poor patient outcomes, and that ADAR1-mediated editing of GLI1 is a mechanism relevant in the context of multiple myeloma progression and drug resistance.
Collapse
Affiliation(s)
- Elisa Lazzari
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Phoebe K Mondala
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Nathaniel Delos Santos
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Amber C Miller
- Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA
| | - Gabriel Pineda
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA.,Department of Health Sciences, School of Health and Human Services at National University, San Diego, CA, 92123, USA
| | - Qingfei Jiang
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Heather Leu
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Shawn A Ali
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Anusha-Preethi Ganesan
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Christina N Wu
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA
| | - Caitlin Costello
- Department of Medicine, Moores Cancer Center at University of California, San Diego, La Jolla, CA, 92093, USA
| | - Mark Minden
- Princess Margaret Hospital, University Health Network, Toronto, ON, Canada, M5G 2M9
| | | | - A Keith Stewart
- Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA
| | - Leslie A Crews
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA.
| | - Catriona H M Jamieson
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92037, USA. .,Department of Medicine, Moores Cancer Center at University of California, San Diego, La Jolla, CA, 92093, USA.
| |
Collapse
|
12
|
Garavelli S, Lazzari E, Colombo M, Platonova N, Palano MT, Baccianti F, Galletti S, Neri A, Crews L, Jamieson C, Chiaramonte R. Abstract LB-025: The role of NOTCH pathway in multiple myeloma associated drug resistance. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-lb-025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The aim of this study was to investigate the role of Notch signaling in intrinsic and bone marrow stromal cells (BMSC)-mediated drug resistance in multiple myeloma (MM) and in MM-stem cell (SC) niche maintenance.
MM is an incurable hematological malignancy due to intrinsic or BMSC-mediated drug resistance; the hyperexpression of two Notch ligands, Jag1 and 2 in MM increases Notch signaling in MM cells and BMSCs resulting in malignant cells survival and proliferation. Notch pathway supports stem cell maintenance and drug resistance is an intrinsic feature of cancer stem cells; MM stem cells (MM-SCs) have been characterized as CD138- subpopulation. MM-SCs are resistant to common drugs used in therapy and responsible for disease relapse.
MM cell lines were cultured alone or co-cultured with NIH3T3 murine fibroblasts or HS5 human BMSC line. To detect apoptosis induced by Mitoxantrone, Bortezomib and Melphalan, AnnexinV+ cells were processed by flow cytometry (FC). Jag1 and Jag2 were transiently silenced in MM cells using specific siRNAs. The gene expression levels were analyzed by quantitative RT-PCR. Anti-apoptotic proteins were assessed by FC. Notch inhibition was obtained by γ-secretase inhibitor and the effect on MM cell stemness potential of was assessed by FC measure of CD138- MM cells or clonogenic serial replating in methylcellulose-based medium.
Our results demonstrate that Jag1 and 2 silencing reduces anti-apoptotic genes expression, i.e. SDF1α, CXCR4, Bcl-XL, Bcl2, Survivin and ABCC1 and increases sensitivity of MM cells to the used drugs. MM cells and BMSCs reciprocally activate Notch signaling resulting in increased drug resistance due to: i) an elevated expression of the anti-apoptotic genes in MM cells; ii) BMSCs release of soluble factors, i.e. SDF1α and VEGF, relevant for MM cell growth and survival. Interestingly, Jag1 and 2 silencing in MM cells co-cultured with BMSCs could reverse all gene and protein expression changes as well as BMSCs protective effect increasing the apoptotic rate of MM cells. In addition, we show in MM cell lines that DAPT-mediated Notch inhibition decreases MM-SCs and reduces the clonogenic ability in serial replating.
The evidence that Jag1 and 2 silencing affects the intrinsic and BMSC-induced drug resistance in MM cells also by affecting the MM-SC population supports the rationale for a Notch-tailored approach to overcome the unavoidable relapse pf MM patient.
Citation Format: Silvia Garavelli, Elisa Lazzari, Michela Colombo, Natalia Platonova, Maria Teresa Palano, Francesco Baccianti, Serena Galletti, Antonino Neri, Leslie Crews, Catriona Jamieson, Raffaella Chiaramonte. The role of NOTCH pathway in multiple myeloma associated drug resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr LB-025. doi:10.1158/1538-7445.AM2017-LB-025
Collapse
|
13
|
Lazzari E, Santos ND, Wu C, Leu H, Pineda G, Ali S, Costello C, Minden M, Chiaramonte R, Crews L, Jamieson C. Abstract 3351: Aberrant RNA editing of GLI1 promotes malignant regeneration in multiple myeloma. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-3351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Despite novel therapies, most of multiple myeloma (MM) patients relapse as a result of clonal evolution in inflammatory microenvironments. Adenosine-to-inosine (A-to-I) RNA editing, driven by inflammatory cytokine-responsive adenosine deaminase acting on RNA1 (ADAR1), promotes cancer progression by enhancing survival and self-renewal of malignant progenitor cells. Amplifications of chromosome 1q21, containing IL-6R and ADAR1 loci, occur frequently in high-risk MM patients, who frequently develop secondary plasma cell leukemia (PCL) and have shorter survival. While increased IL-6 signaling has been linked to relapse and A-to-I editing contributes to therapeutic resistance in a broad array of malignancies, the role of ADAR1 in MM pathogenesis has not been elucidated. This study aimed to investigate whether pro-inflammatory cues in MM activate ADAR1 editing thereby promoting malignant regeneration.
Procedures: Publicly available primary patient datasets were analyzed and validated in a separate cohort of biobanked primary samples and human myeloma cell lines. Lentiviral vector-mediated activation or knockdown of ADAR1, or treatment with extrinsic pro-inflammatory stimuli, was utilized to probe the functional impact of RNA editing activity in MM models. Site-specific qPCR was used to quantify RNA editing in specific cancer stem cell-associated loci. Functional effects of ADAR1 activity were assessed in in vitro survival and self-renewal assays, and in novel in vivo PCL xenografts.
Results: Patients harboring 1q21 amplification showed significant and stage-dependent increases in ADAR1 expression. In a set of separate primary PCL samples, aberrant RNA editing in the coding region of the Hedgehog (Hh) pathway transcription factor GLI1 was observed in high ADAR1-expressing samples. Notably, increased GLI1 editing, previously reported to have increased capacity to activate its transcriptional targets, was detected in serially transplantable, patient-derived xenograft models. Furthermore, abolition of ADAR1 editase activity impaired GLI1 editing. Lastly, in vitro pro-inflammatory IL-6 stimulation, or continuous exposure to the immunomodulatory drug lenalidomide led to increased ADAR1 mRNA and protein levels, with a concomitant induction of RNA editing activity.
Conclusions: In MM, 1q21 amplification has been linked to progression. We provide new evidence linking expression and activity of ADAR1, located on 1q21, and disease stage. Because ADAR1 induces transcript recoding, A-to-I editing could contribute to the marked transcriptomic diversity typical of advanced MM. While the Hh pathway has been linked to cancer stem cell generation in human MM, here we identified a primate-specific mechanism of Hh pathway activation in MM through RNA editing-dependent stabilization of GLI1. Together, both genetic and microenvironmental factors modulate epitranscriptomic deregulation of cancer stem cell pathways in MM.
Citation Format: Elisa Lazzari, Nathaniel Delos Santos, Christina Wu, Heather Leu, Gabriel Pineda, Shawn Ali, Caitlin Costello, Mark Minden, Raffaella Chiaramonte, Leslie Crews, Catriona Jamieson. Aberrant RNA editing of GLI1 promotes malignant regeneration in multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3351. doi:10.1158/1538-7445.AM2017-3351
Collapse
Affiliation(s)
| | | | - Christina Wu
- 1University of California, San Diego, San Diego, CA
| | - Heather Leu
- 1University of California, San Diego, San Diego, CA
| | | | - Shawn Ali
- 1University of California, San Diego, San Diego, CA
| | | | - Mark Minden
- 2University of Toronto, Toronto, Ontario, Canada
| | | | - Leslie Crews
- 1University of California, San Diego, San Diego, CA
| | | |
Collapse
|
14
|
Lazzari E, Meroni G. TRIM32 ubiquitin E3 ligase, one enzyme for several pathologies: From muscular dystrophy to tumours. Int J Biochem Cell Biol 2016; 79:469-477. [PMID: 27458054 DOI: 10.1016/j.biocel.2016.07.023] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Revised: 07/20/2016] [Accepted: 07/21/2016] [Indexed: 01/01/2023]
Abstract
TRIM32 is a member of the TRIpartite Motif family characterised by the presence of an N-terminal three-domain-module that includes a RING domain, which confers E3 ubiquitin ligase activity, one or two B-box domains and a Coiled-Coil region that mediates oligomerisation. Several TRIM32 substrates were identified including muscular proteins and proteins involved in cell cycle regulation and cell motility. As ubiquitination is a versatile post-translational modification that can affect target turnover, sub-cellular localisation or activity, it is likely that diverse substrates may be differentially affected by TRIM32-mediated ubiquitination, reflecting its multi-faceted roles in muscle physiology, cancer and immunity. With particular relevance for muscle physiology, mutations in TRIM32 are associated with autosomal recessive Limb-Girdle Muscular Dystrophy 2H, a muscle-wasting disease with variable clinical spectrum ranging from almost asymptomatic to wheelchair-bound patients. In this review, we will focus on the ability of TRIM32 to mark specific substrates for proteasomal degradation discussing how the TRIM32-proteasome axis may (i) be important for muscle homeostasis and for the pathogenesis of muscular dystrophy; and (ii) define either an oncogenic or tumour suppressive role for TRIM32 in the context of different types of cancer.
Collapse
Affiliation(s)
- Elisa Lazzari
- Department of Life Sciences, University of Trieste and Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy
| | - Germana Meroni
- Department of Life Sciences, University of Trieste and Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
| |
Collapse
|
15
|
Lazzari E, Crews LA, Wu C, Leu H, Ali S, Chiaramonte R, Minden M, Costello C, Jamieson CH. Abstract 2414: ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-2414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Multiple myeloma (MM) is a plasma cell malignancy that accounts for more than 10% of all blood cancers and may progress to plasma cell leukemia (PCL). Despite treatment, virtually all patients become unresponsive to treatment. RNA editing is a post-transcriptional pre-mRNA processing activity that represents an unexplored potential source of clonal molecular heterogeneity contributing to therapeutic resistance. In particular, adenosine deaminase acting on RNA (ADAR) 1, which exists in two isoforms, one constitutive and one inflammation-responsive, has been associated with disease progression and cancer stem cell (CSC) maintenance. The aim of this study was to investigate whether enhanced ADAR1 expression and activity contributed to therapeutic resistance of MM and PCL.
Procedures
1) ADAR Quantification: Whole gene and isoform-specific qRT-PCR was used to detect ADAR1 expression in PCL and MM primary samples and in human MM cell lines (HMCL).
2) RNA Editing Detection: We developed a RNA editing site-specific qPCR (RESS-qPCR) assay to detect RNA editing in cancer stem-cell associated transcripts.
3) Therapeutic Resistance Assay. A MM cell line was exposed to lenalidomide continuously in vitro to establish a model of therapeutic resistance.
4) Development of a humanized PCL mouse model: We established novel in vivo PCL primagrafts by intrahepatic transplantation of primary total mononuclear cells into neonatal RAG2-/-gc-/- mice.
Results
Approximately, 30% of MM patients in the MM Genomic Initiative dataset harbor copy number amplifications of the ADAR locus on chromosome 1q21, which portends a poor prognosis. We observed significantly increased ADAR1 expression in primary PCL samples and aberrant RNA editing of the stem cell transcription factor GLI1 and the DNA cytidine deaminase APOBEC3D. Notably, high-ADAR1-expressing PCL cells successfully engrafted in RAG2-/-gc-/- mice. As the inflammation-responsive isoform of ADAR1 was upregulated in primary samples, we sought to explore the effects of the anti-MM agent and immunomodulatory drug lenalidomide on ADAR1 expression and activity. Continuous in vitro exposure to lenalidomide led to increased ADAR1 mRNA and protein level and a potent induction of RNA editing activity. Increased RNA editing was detected in several cancer and stem cell-associated transcripts, including GLI1, APOBEC3D, AZIN1 and MDM2. Notably, this aberrant RNA editing activity was associated with increased self-renewal capacity in vitro and a cancer stem cell phenotype.
Conclusions
ADAR1 overexpression and deregulated RNA editing represents a unique source of RNA and proteomic diversity, and may confer a survival and self-renewal advantage to MM cells. This research identifies ADAR1 as a new diagnostic and therapeutic target in MM, and establishes a robust humanized PCL primagraft model for future pre-clinical testing of ADAR1 modulatory agents.
Citation Format: Elisa Lazzari, Leslie A. Crews, Christina Wu, Heather Leu, Shawn Ali, Raffaella Chiaramonte, Mark Minden, Caitlin Costello, Catriona H.M. Jamieson. ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2414.
Collapse
Affiliation(s)
- Elisa Lazzari
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | - Leslie A. Crews
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | - Christina Wu
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | - Heather Leu
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | - Shawn Ali
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | | | - Mark Minden
- 3Princess Margaret Hospital, University Health Network, Toronto, Canada
| | - Caitlin Costello
- 4Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| | - Catriona H.M. Jamieson
- 1Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, San Diego, San Diego, CA
| |
Collapse
|
16
|
Pineda G, Lennon KM, Delos Santos NP, Lambert-Fliszar F, Riso GL, Lazzari E, Marra MA, Morris S, Sakaue-Sawano A, Miyawaki A, Jamieson CHM. Tracking of Normal and Malignant Progenitor Cell Cycle Transit in a Defined Niche. Sci Rep 2016; 6:23885. [PMID: 27041210 PMCID: PMC4819192 DOI: 10.1038/srep23885] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 03/10/2016] [Indexed: 11/09/2022] Open
Abstract
While implicated in therapeutic resistance, malignant progenitor cell cycle kinetics have been difficult to quantify in real-time. We developed an efficient lentiviral bicistronic fluorescent, ubiquitination-based cell cycle indicator reporter (Fucci2BL) to image live single progenitors on a defined niche coupled with cell cycle gene expression analysis. We have identified key differences in cell cycle regulatory gene expression and transit times between normal and chronic myeloid leukemia progenitors that may inform cancer stem cell eradication strategies.
Collapse
Affiliation(s)
- Gabriel Pineda
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| | - Kathleen M Lennon
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| | - Nathaniel P Delos Santos
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| | - Florence Lambert-Fliszar
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| | - Gennarina L Riso
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA.,Biological Sciences Department, California Polytechnic State University, San Luis Obispo, CA, 93407, USA
| | - Elisa Lazzari
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA.,Doctoral School of Molecular and Translational Medicine, Department of Health Sciences, University of Milan, Milan, Italy
| | - Marco A Marra
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada
| | - Sheldon Morris
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| | - Asako Sakaue-Sawano
- Laboratory for Cell Function and Dynamics, Brain Science Institute, RIKEN, Wako-city, Saitama, Japan
| | - Atsushi Miyawaki
- Laboratory for Cell Function and Dynamics, Brain Science Institute, RIKEN, Wako-city, Saitama, Japan
| | - Catriona H M Jamieson
- Divisions of Regenerative Medicine and Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093-0820, USA
| |
Collapse
|
17
|
Ludwig K, Alaggio R, Dall'Igna P, Lazzari E, d'Amore ESG, Chou PM. Omental mesenteric myxoid hamartoma, a subtype of inflammatory myofibroblastic tumor? Considerations based on the histopathological evaluation of four cases. Virchows Arch 2015; 467:741-747. [PMID: 26386568 DOI: 10.1007/s00428-015-1842-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Revised: 07/26/2015] [Accepted: 08/20/2015] [Indexed: 12/11/2022]
Abstract
Omental mesenteric myxoid hamartoma (OMH) is a distinctive myxoid lesion of infancy, characterized by a benign clinical behavior. In the current World Health Organization (WHO) classification of soft tissue tumors, it is considered as part of the morphologic spectrum of inflammatory myofibroblastic tumors (IMT), but this relationship with IMT is still subject to debate. Four lesions with histologic features of OMH occurring in newborns and toddlers are described and compared with classic, ALK-positive IMT. All OMH showed a peculiar dot-like immunostaining for ALK, which, in one of the cases, was cytogenetically found to be associated with an inversion of the ALK gene. While OMHs were positive for smooth muscle actin (SMA), desmin, WT1, podoplanin, and cytokeratins (CAM5.2 and AE1-3), IMT were consistently positive only for SMA (10 cases). ALK-1 displayed cytoplasmic staining in IMT and characteristic paranuclear dot-like staining in OMH.
Collapse
Affiliation(s)
- K Ludwig
- Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University-Hospital of Padua, Via A. Gabelli 61, 35121, Padua, Italy
| | - R Alaggio
- Department of Medicine (DIMED), Surgical Pathology & Cytopathology Unit, University-Hospital of Padua, Via A. Gabelli 61, 35121, Padua, Italy.
| | - P Dall'Igna
- Department of Woman and Children's Health, Pediatric Surgery Unit, University-Hospital of Padua, Via Giustiniani 3, 35121, Padua, Italy
| | - E Lazzari
- Pathology Department, "San Bortolo" Hospital, Vicenza, Viale Rodolfi 37, 36100, Vicenza, Italy
| | - E S G d'Amore
- Pathology Department, "San Bortolo" Hospital, Vicenza, Viale Rodolfi 37, 36100, Vicenza, Italy
| | - P M Chou
- Department of Pathology, Northwestern University, 303 East Chicago Avenue, Chicago, IL, 60611, USA
| |
Collapse
|
18
|
Colombo M, Thümmler K, Mirandola L, Garavelli S, Todoerti K, Apicella L, Lazzari E, Lancellotti M, Platonova N, Akbar M, Chiriva-Internati M, Soutar R, Neri A, Goodyear CS, Chiaramonte R. Notch signaling drives multiple myeloma induced osteoclastogenesis. Oncotarget 2015; 5:10393-406. [PMID: 25257302 PMCID: PMC4279381 DOI: 10.18632/oncotarget.2084] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Accepted: 06/07/2014] [Indexed: 11/30/2022] Open
Abstract
Multiple myeloma (MM) is closely associated with bone destruction. Once migrated to the bone marrow, MM cells unbalance bone formation and resorption via the recruitment and maturation of osteoclast precursors. The Notch pathway plays a key role in different types of cancer and drives several biological processes relevant in MM, including cell localization within the bone marrow, proliferation, survival and pharmacological resistance. Here we present evidences that MM can efficiently drive osteoclastogenesis by contemporaneously activating Notch signaling on tumor cells and osteoclasts through the aberrant expression of Notch ligands belonging to the Jagged family. Active Notch signaling in MM cells induces the secretion of the key osteoclastogenic factor, RANKL, which can be boosted in the presence of stromal cells. In turn, MM cells-derived RANKL causes the upregulation of its receptor, RANK, and Notch2 in pre-osteoclasts. Notch2 stimulates osteoclast differentiation by promoting autocrine RANKL signaling. Finally, MM cells through Jagged ligands expression can also activate Notch signaling in pre-osteoclast by direct contact. Such synergism between tumor cells and pre-osteoclasts in MM-induced osteoclastogenesis can be disrupted by silencing tumor-derived Jagged1 and 2. These results make the Jagged ligands new promising therapeutic targets in MM to contrast bone disease and the associated co-morbidities.
Collapse
Affiliation(s)
- Michela Colombo
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | - Katja Thümmler
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Leonardo Mirandola
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | - Silvia Garavelli
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | - Katia Todoerti
- Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy
| | - Luana Apicella
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | - Elisa Lazzari
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | | | - Natalia Platonova
- Department of Health Sciences, Università degli Studi di Milano, Milano, Italy
| | - Moeed Akbar
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | - Maurizio Chiriva-Internati
- Division of Hematology and Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, TX, USA
| | - Richard Soutar
- Beatson West of Scotland Cancer Centre, Haemato-oncology Service, Gartnavel Hospital, Glasgow, UK
| | - Antonino Neri
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano; Hematology, Fondazione Cà Granda IRCCS Policlinico, Milano, Italy
| | - Carl S Goodyear
- Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
| | | |
Collapse
|
19
|
Platonova N, Manzo T, Mirandola L, Colombo M, Calzavara E, Vigolo E, Cermisoni GC, De Simone D, Garavelli S, Cecchinato V, Lazzari E, Neri A, Chiaramonte R. PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation. Genes Chromosomes Cancer 2015; 54:516-526. [DOI: 10.1002/gcc.22264] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2014] [Accepted: 04/08/2015] [Indexed: 01/27/2023] Open
Affiliation(s)
- Natalia Platonova
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Teresa Manzo
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Leonardo Mirandola
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Michela Colombo
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Elisabetta Calzavara
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Emilia Vigolo
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Greta Chiara Cermisoni
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Daria De Simone
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Silvia Garavelli
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Valentina Cecchinato
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Elisa Lazzari
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| | - Antonino Neri
- Department of Clinical Sciences and Community Health; Università Degli Studi Di Milano; Hematology, Fondazione Cà Granda IRCCS Policlinico; via F. Sforza 35 20122 Milan Italy
| | - Raffaella Chiaramonte
- Department of Health Science; Università Degli Studi Di Milano; via A. Di Rudinì 8 20142 Milan Italy
| |
Collapse
|
20
|
Crews LA, Jiang Q, Zipeto MA, Lazzari E, Court AC, Ali S, Barrett CL, Frazer KA, Jamieson CHM. An RNA editing fingerprint of cancer stem cell reprogramming. J Transl Med 2015; 13:52. [PMID: 25889244 PMCID: PMC4341880 DOI: 10.1186/s12967-014-0370-3] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 12/19/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Deregulation of RNA editing by adenosine deaminases acting on dsRNA (ADARs) has been implicated in the progression of diverse human cancers including hematopoietic malignancies such as chronic myeloid leukemia (CML). Inflammation-associated activation of ADAR1 occurs in leukemia stem cells specifically in the advanced, often drug-resistant stage of CML known as blast crisis. However, detection of cancer stem cell-associated RNA editing by RNA sequencing in these rare cell populations can be technically challenging, costly and requires PCR validation. The objectives of this study were to validate RNA editing of a subset of cancer stem cell-associated transcripts, and to develop a quantitative RNA editing fingerprint assay for rapid detection of aberrant RNA editing in human malignancies. METHODS To facilitate quantification of cancer stem cell-associated RNA editing in exons and intronic or 3'UTR primate-specific Alu sequences using a sensitive, cost-effective method, we established an in vitro RNA editing model and developed a sensitive RNA editing fingerprint assay that employs a site-specific quantitative PCR (RESSq-PCR) strategy. This assay was validated in a stably-transduced human leukemia cell line, lentiviral-ADAR1 transduced primary hematopoietic stem and progenitor cells, and in primary human chronic myeloid leukemia stem cells. RESULTS In lentiviral ADAR1-expressing cells, increased RNA editing of MDM2, APOBEC3D, GLI1 and AZIN1 transcripts was detected by RESSq-PCR with improved sensitivity over sequencing chromatogram analysis. This method accurately detected cancer stem cell-associated RNA editing in primary chronic myeloid leukemia samples, establishing a cancer stem cell-specific RNA editing fingerprint of leukemic transformation that will support clinical development of novel diagnostic tools to predict and prevent cancer progression. CONCLUSIONS RNA editing quantification enables rapid detection of malignant progenitors signifying cancer progression and therapeutic resistance, and will aid future RNA editing inhibitor development efforts.
Collapse
Affiliation(s)
- Leslie A Crews
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| | - Qingfei Jiang
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| | - Maria A Zipeto
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| | - Elisa Lazzari
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA. .,Doctoral School of Molecular and Translational Medicine, Department of Health Sciences, University of Milan, Milan, Italy.
| | - Angela C Court
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| | - Shawn Ali
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| | - Christian L Barrett
- Division of Genome Information Sciences, Department of Pediatrics, University of California, La Jolla, CA, 92093, USA.
| | - Kelly A Frazer
- Division of Genome Information Sciences, Department of Pediatrics, University of California, La Jolla, CA, 92093, USA.
| | - Catriona H M Jamieson
- Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center at University of California, La Jolla, CA, 92093, USA. .,Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.
| |
Collapse
|
21
|
Wynne C, Lazzari E, Smith S, McCarthy EM, Ní Gabhann J, Kallal LE, Higgs R, Cryan SA, Biron CA, Jefferies CA. TRIM68 negatively regulates IFN-β production by degrading TRK fused gene, a novel driver of IFN-β downstream of anti-viral detection systems. PLoS One 2014; 9:e101503. [PMID: 24999993 PMCID: PMC4084880 DOI: 10.1371/journal.pone.0101503] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Accepted: 06/08/2014] [Indexed: 12/28/2022] Open
Abstract
In recent years members of the tripartite motif-containing (TRIM) family of E3 ubiquitin ligases have been shown to both positively and negatively regulate viral defence and as such are emerging as compelling targets for modulating the anti-viral immune response. In this study we identify TRIM68, a close homologue of TRIM21, as a novel regulator of Toll-like receptor (TLR)- and RIG-I-like receptor (RLR)-driven type I IFN production. Proteomic analysis of TRIM68-containing complexes identified TRK-fused gene (TFG) as a potential TRIM68 target. Overexpression of TRIM68 and TFG confirmed their ability to associate, with TLR3 stimulation appearing to enhance the interaction. TFG is a known activator of NF-κB via its ability to interact with inhibitor of NF-κB kinase subunit gamma (IKK-γ) and TRAF family member-associated NF-κB activator (TANK). Our data identifies a novel role for TFG as a positive regulator of type I IFN production and suggests that TRIM68 targets TFG for lysosomal degradation, thus turning off TFG-mediated IFN-β production. Knockdown of TRIM68 in primary human monocytes resulted in enhanced levels of type I IFN and TFG following poly(I:C) treatment. Thus TRIM68 targets TFG, a novel regulator of IFN production, and in doing so turns off and limits type I IFN production in response to anti-viral detection systems.
Collapse
Affiliation(s)
- Claire Wynne
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
- School of Biological Sciences, Dublin Institute of Technology, Dublin, Ireland
| | - Elisa Lazzari
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Siobhán Smith
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Eoghan M. McCarthy
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Joan Ní Gabhann
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Lara E. Kallal
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, United States of America
| | - Rowan Higgs
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Sally Ann Cryan
- School of Pharmacy, Royal College of Surgeons in Ireland, Dublin, Ireland
- Trinity Centre for Bioengineering, Trinity College Dublin, Dublin, Ireland
| | - Christine A. Biron
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island, United States of America
| | - Caroline A. Jefferies
- Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
| |
Collapse
|
22
|
Abstract
Transcription of the type I IFN genes is regulated by members of the Interferon Regulatory Factor (IRF) family of transcription factors, composed in humans of 9 distinct proteins. In addition to IRF3 and IRF7, the transcription factor IRF5 has been shown to be involved in type I IFN production and interestingly, polymorphisms of the IRF5 gene in humans can result in risk or protective haplotypes with regard to SLE susceptibility. In addition to regulation of type I IFN expression, IRF5 is involved in other signaling pathways, including IgG switching in B cells, macrophage polarization and apoptosis, and its role in SLE pathogenesis may therefore not be limited to dysregulated control of IFN expression. In this review we will comprehensively discuss the role of IRF5 in immune-mediated responses and its potential multifaceted role in conferring SLE susceptibility.
Collapse
Affiliation(s)
- Elisa Lazzari
- Molecular and Cellular Therapeutics, Research Institute, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland.
| | - Caroline A Jefferies
- Molecular and Cellular Therapeutics, Research Institute, Royal College of Surgeons in Ireland, 123 St Stephen's Green, Dublin 2, Ireland.
| |
Collapse
|
23
|
Mirandola L, Chiriva-Internati M, Cobos E, Yu Y, Figueroa JA, Garavelli S, Colombo M, Lazzari E, Platonova N, Zepeda K, Jumper CA, Jenkins M, Alalawi R, Konala V, Aulakh A, Radhi S, Chiaramonte R. Chemokine receptors as novel targets of the oncogene Notch1 in acute lymphoblastic leukemia. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.7060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7060 Background: Malignant cells from different cancers express different profiles of chemokine receptors (CKR). Their presence may influence site-specific spread of tumor cells, by enabling them to respond to chemokine gradient, and may increase cell sensibility to chemokine mediated proliferative and anti-apoptotic stimuli. Notch ability to positively regulate CKR has been reported: stimulation of Pax5-/- pre-B cells with the Notch ligand Delta-1 results in induction of transcripts for CCR4, CCR8 and CXCR 6; the Delta-1-dependent regulation of Langerhans cell development includes induction of CCR6 expression resulting in the activation of chemotactic response to MIP-1a; Notch controls CCR7 signaling a regulator of CNS infiltration in T-acute lymphoblastic leukemia (T-ALL). Methods: This work aims to explore the correlation between the activation of the Notch oncogenic pathway in T-ALL and multiple myeloma (MM) cells and the aberrant expression CKR. Human T-ALL cell lines were treated with the Notch activation inhibitor, DAPT, or with a potent inhibitor of the Notch target, C-MYC, and evaluated the expression and functions of CCR9, CCR5, and CXCR4. Results: Treatment of human T-ALL and MM cell lines with pharmacologic inhibitors of Notch receptor activation produced a significant reduction of CCR9, CCR5 and CXCR4 expression, at both mRNA and protein levels. Results were confirmed by chemotaxis and survival assays. We identified the product of C-MYC gene as a possible mediator of Notch effect in regulating CKR networks in T-ALL and MM. Conclusions: These results suggest that Notch receptors play a previously unknown role in cancer progression and metastasis, by maintaining the expression levels of CKR. In conclusion, the identification of the potential axis Notch/CKR could have a prognostic value and provide the rationale for a tailored approach, since both Notch and CKR are targeted by emerging drugs.
Collapse
Affiliation(s)
- Leonardo Mirandola
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | - Everardo Cobos
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Yuefei Yu
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Jose A. Figueroa
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | | | | | - Kristopher Zepeda
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | - Raed Alalawi
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Venu Konala
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Amardeep Aulakh
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Saba Radhi
- Texas Tech University Health Sciences Center, Lubbock, TX
| | | |
Collapse
|
24
|
Chiriva-Internati M, Mirandola L, Lazzari E, Colombo M, Lancellotti M, Cobos E, Yu Y, Figueroa JA, Saadeh C, Wade R, Zepeda K, Mer J, Konala V, Radhi S, Aulakh A, Jenkins M, Jumper CA, Alalawi R, Chiaramonte R. Promotion of human multiple myeloma cell growth in vitro and bone marrow invasion in vivo by Notch receptors and the CXCR4/SDF1 axis. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.8591] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8591 Background: Multiple myeloma (MM) originates from post-germinal center B cells, and is caused by malignant plasma cells accumulating in the bone marrow. Interactions of MM cells with the bone marrow stroma promote tumor growth, migration and drug resistance. The chemokine receptor CXCR4 and its ligand SDF1 are critical regulators of this process. MM cells frequently hyper-express CXCR4 and respond to SDF1,2 enhancing MM cell infiltration, proliferation and osteolysis. Notch receptors similarly promote MM cell growth, drug resistance and the associated osteolytic process. We hypothesized that the CXCR4/SDF1 axis mediates the effects of Notch signals in MM. Methods: We used real-time PCR, flow-cytometry, E.L.I.S.A. and chemotaxis assay to explore the effects of CXCR4 in cultured human MM cell lines after Notch inhibition or over-stimulation. Additionally, we validated our findings in a NOD/SCID murine model xenografted with human MM cells. Results: Our results show that Notch blocking reduced CXCR4 and SDF1 expression by MM cells. Further, Notch activation was required for MM cell chemotactic and proliferative response to SDF1 in vitro. We then investigated the outcome of anti-Notch treatment on human MM cells bone invasion in NOD/SCID mice. Interfering with Notch activity dramatically reduced xenografted MM cell ability to infiltrate the bone marrow, ultimately resulting in diminished tumor burden. Notably, such effect was associated with a decrease of CXCR4 expression. Conclusions: This was the first time that Notch receptors were reported to regulate the CXCR4/SDF1 axis and bone marrow invasion in human MM. These findings indicate that specific Notch-tailored therapies may effectively hamper CXCR4-mediated bone infiltration and associated lesions, and are expected to significantly improve treatment outcome and survival.
Collapse
Affiliation(s)
| | - Leonardo Mirandola
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | | | - Everardo Cobos
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Yuefei Yu
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Jose A. Figueroa
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Charles Saadeh
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Raymond Wade
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Kristopher Zepeda
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Jesse Mer
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Venu Konala
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Saba Radhi
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Amardeep Aulakh
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | - Raed Alalawi
- Texas Tech University Health Sciences Center, Lubbock, TX
| | | |
Collapse
|
25
|
Konala V, Platonova N, Colombo M, Mirandola L, Lazzari E, De Simone D, Radhi S, Aulakh A, Zepeda K, Wade R, Mer J, Saadeh C, Yu Y, Jenkins M, Figueroa JA, Cobos E, Chiriva-Internati M, Chiaramonte R. Relationship of the oncogene Notch and CXCR4/SDF1 signaling in human epithelial ovarian cancer. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e22003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e22003 Background: Ovarian cancer (OC) is the most aggressive gynecologic cancer. Understanding OC molecular pathogenesis is critical to provide novel therapeutic strategies. We aim to elucidate Notch oncogenic role in OC by focusing on its extensive crosstalk with other important pathways as CXCR4/SDF1alpha chemokine system whose involvement in OC development and metastasis is well recognized. Methods: We used flow-cytometry, cell cycle analysis, real-time PCR, and Transwell chemotaxis assay to investigate the outcome of Notch signaling withdrawal on tumor cell response to CXCR4 and SDF1alpha. Results: The analyzed OC cell lines expressed high levels of CXCR4 and its ligand SDF1alpha. Treatment with DAPT, an inhibitor of Notch activity, reduced OC cell proliferation and blocked cell cycle in G0/G1 phase without affecting apoptosis. In addition, Notch withdrawal diminished CXCR4 and SDF1alpha expression levels and hampered SDF1-driven migration and proliferation. Conclusions: Notch deregulation might affect important features of OC such as cell growth and migration through the modulation of CXCR4/SDF1a pathway. This indicates that these intertwined pathways are promising therapeutic targets in OC.
Collapse
Affiliation(s)
- Venu Konala
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | - Leonardo Mirandola
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | | | | | - Saba Radhi
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Amardeep Aulakh
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Kristopher Zepeda
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Raymond Wade
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Jesse Mer
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Charles Saadeh
- Texas Tech University Health Sciences Center, Lubbock, TX
| | - Yuefei Yu
- Texas Tech University Health Sciences Center, Lubbock, TX
| | | | - Jose A. Figueroa
- Texas Tech University Health Sciences Center and the Southwest Cancer Treatment and Research Center, Lubbock, TX
| | - Everardo Cobos
- Texas Tech University Health Sciences Center, Lubbock, TX
| | | | | |
Collapse
|
26
|
Mirandola L, Apicella L, Colombo M, Yu Y, Berta DG, Platonova N, Lazzari E, Lancellotti M, Bulfamante G, Cobos E, Chiriva-Internati M, Chiaramonte R. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1. Leukemia 2013; 27:1558-66. [PMID: 23354012 DOI: 10.1038/leu.2013.27] [Citation(s) in RCA: 70] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2012] [Revised: 01/14/2013] [Accepted: 01/17/2013] [Indexed: 01/10/2023]
Abstract
Multiple myeloma (MM) is a deadly hematopoietic malignancy characterized by proliferation of malignant plasma cells in the bone marrow (BM) and bone disease. Interactions between myeloma and BM cells facilitate tumor progression and resistance to therapies. CXCR4 and its ligand Stromal cell-derived factor-1 (SDF-1) have a primary role in this process and are associated with poor prognosis. The Notch pathway is active in myeloma cells, resulting in increased proliferation, resistance to apoptosis and osteolytic activity. We hypothesized that the CXCR4/SDF-1 axis mediates the effects of Notch signals in myeloma cells. Here we show that Notch positively controls CXCR4/SDF-1 expression and functions in myeloma cell lines, and that forced CXCR4 activation partially rescues tumor cells from the outcomes of Notch inhibition. Additionally, we provide evidences that Notch blocking in vivo significantly reduces BM infiltration by human myeloma cells in mouse xenografts. This is the first evidence that a Notch-targeted approach effectively prevents MM cell migration, proliferation and resistance to apoptosis by reducing CXCR4 and SDF-1 levels.
Collapse
Affiliation(s)
- L Mirandola
- Department of Health Sciences, Università degli Studi di Milano, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Meehan M, Parthasarathi L, Moran N, Jefferies CA, Foley N, Lazzari E, Murphy D, Ryan J, Ortiz B, Fabius AWM, Chan TA, Stallings RL. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer 2012; 11:6. [PMID: 22305495 PMCID: PMC3395855 DOI: 10.1186/1476-4598-11-6] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2011] [Accepted: 02/05/2012] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Protein tyrosine phosphatase receptor delta (PTPRD) is a member of a large family of protein tyrosine phosphatases which negatively regulate tyrosine phosphorylation. Neuroblastoma is a major childhood cancer arising from precursor cells of the sympathetic nervous system which is known to acquire deletions and alterations in the expression patterns of PTPRD, indicating a potential tumor suppressor function for this gene. The molecular mechanism, however, by which PTPRD renders a tumor suppressor effect in neuroblastoma is unknown. RESULTS As a molecular mechanism, we demonstrate that PTPRD interacts with aurora kinase A (AURKA), an oncogenic protein that is over-expressed in multiple forms of cancer, including neuroblastoma. Ectopic up-regulation of PTPRD in neuroblastoma dephosphorylates tyrosine residues in AURKA resulting in a destabilization of this protein culminating in interfering with one of AURKA's primary functions in neuroblastoma, the stabilization of MYCN protein, the gene of which is amplified in approximately 25 to 30% of high risk neuroblastoma. CONCLUSIONS PTPRD has a tumor suppressor function in neuroblastoma through AURKA dephosphorylation and destabilization and a downstream destabilization of MYCN protein, representing a novel mechanism for the function of PTPRD in neuroblastoma.
Collapse
Affiliation(s)
- Maria Meehan
- Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Dublin, Ireland
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Higgs R, Lazzari E, Wynne C, Ní Gabhann J, Espinosa A, Wahren-Herlenius M, Jefferies CA. Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 2010; 5:e11776. [PMID: 20668674 PMCID: PMC2909902 DOI: 10.1371/journal.pone.0011776] [Citation(s) in RCA: 105] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Accepted: 07/01/2010] [Indexed: 12/23/2022] Open
Abstract
Ro52 is a member of the TRIM family of single-protein E3 ligases and is also a target for autoantibody production in systemic lupus erythematosus and Sjögren's syndrome. We previously demonstrated a novel function of Ro52 in the ubiquitination and proteasomal degradation of IRF3 following TLR3/4 stimulation. We now present evidence that Ro52 has a similar role in regulating the stability and activity of IRF7. Endogenous immunoprecipitation of Ro52-bound proteins revealed that IRF7 associates with Ro52, an effect which increases following TLR7 and TLR9 stimulation, suggesting that Ro52 interacts with IRF7 post-pathogen recognition. Furthermore, we show that Ro52 ubiquitinates IRF7 in a dose-dependent manner, resulting in a decrease in total IRF7 expression and a subsequent decrease in IFN-α production. IRF7 stability was increased in bone marrow-derived macrophages from Ro52-deficient mice stimulated with imiquimod or CpG-B, consistent with a role for Ro52 in the negative regulation of IRF7 signalling. Taken together, these results suggest that Ro52-mediated ubiquitination promotes the degradation of IRF7 following TLR7 and TLR9 stimulation. As Ro52 is known to be IFN-inducible, this system constitutes a negative-feedback loop that acts to protect the host from the prolonged activation of the immune response.
Collapse
Affiliation(s)
- Rowan Higgs
- Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Elisa Lazzari
- Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Claire Wynne
- Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Joan Ní Gabhann
- Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
| | | | | | - Caroline A. Jefferies
- Molecular and Cellular Therapeutics and RSCI Research Institute, Royal College of Surgeons in Ireland, Dublin, Ireland
- * E-mail:
| |
Collapse
|
29
|
Lazzari E, Casella G, Cortesi R, Ghilardi L. [Occluso-postural diagnostic-therapeutic coordination]. Attual Dent 1991; 7:14-6. [PMID: 2049163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
30
|
Casella G, Lazzari E. [Postural function of occlusion]. Attual Dent 1991; 7:8-12. [PMID: 2049161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
31
|
Arcamone FM, Animati F, Barbieri B, Configliacchi E, D'Alessio R, Geroni C, Giuliani FC, Lazzari E, Menozzi M, Mongelli N. Synthesis, DNA-binding properties, and antitumor activity of novel distamycin derivatives. J Med Chem 1989; 32:774-8. [PMID: 2590277 DOI: 10.1021/jm00124a008] [Citation(s) in RCA: 108] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
A group of potential alkylating agents have been synthesized that are structurally related to the oligopeptide antiviral antibiotic distamycin. All derivatives form complexes with native calf-thymus DNA but compounds 2, 3, and 6 give rise to covalent adducts. Cytostatic activity against both human and murine tumor cell lines in vitro is displayed by the new compounds. Compounds 3 and 4 are active on melphalan-resistant L1210 leukemia in mice.
Collapse
Affiliation(s)
- F M Arcamone
- Research and Development, Farmitalia-Carlo Erba, Erbamont Group, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Arcamone F, Lazzari E, Menozzi M, Soranzo C, Verini MA. Synthesis, DNA binding and antiviral activity of distamycin analogues containing different heterocyclic moieties. Anticancer Drug Des 1986; 1:235-44. [PMID: 3450296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
A series of novel distamycin analogues possessing an additional benzene or heterocyclic ring have been synthesised and tested for selective DNA binding properties and antiviral activity. Inhibition of herpes virus in cell culture appears to be related to AT base pair specificity. Some of the new compounds are also more potent than the parent distamycin against Moloney sarcoma virus.
Collapse
Affiliation(s)
- F Arcamone
- Ricerca & Sviluppo Chimico, Farmitalia Carlo Erba, Milan, Italy
| | | | | | | | | |
Collapse
|
33
|
Orsoni G, Nanni Costa A, Lazzari E, Bonomini V. [Immunological changes in insulin-dependent diabetes mellitus]. MINERVA ENDOCRINOL 1986; 11:119-23. [PMID: 3785116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
34
|
Orsoni G, Lazzari E, Raimondi C, Bonomini V. [Endocrine changes in chronic kidney failure]. Minerva Nefrol 1983; 30:27-31. [PMID: 6346140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
35
|
Orsoni G, Capelli M, Ajuti A, Lazzari E. [Endocrine profiles in patients with chronic renal insufficiency under periodic hemodialytic treatment and after renal transplantation]. G Clin Med 1981; 62:242-51. [PMID: 7021293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
36
|
Bargiotti A, Casenelli G, Franchi G, Gioia B, Lazzari E, Redaelli S, Vigevani A, Arcamone F. Synthesis of derivatives of 3-amino-2,3-dideoxy-L-hexoses related to daunosamine (3-amino-2,3,6-trideoxy-L-lyxo-hexose). Carbohydr Res 1977; 58:353-61. [PMID: 912692 DOI: 10.1016/s0008-6215(00)84362-1] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The synthesis is described of 3-amino-2,3-dideoxy-L-arabino-hexose (10), methyl 2,3-dideoxy-alpha-L-lyxo-hexopyranoside(17), methyl 3-amino-2,3-dideoxy-alpha-L-ribo-hexopyranoside (21), methyl 2,3-dideoxy-3-trifluoroacetamido-alpha-L-xylo-hexopyranoside (26), and certain derivatives from methyl 4,6-O-benzylidene-2-deoxy-alpha-L-arabino-hexopyranoside (3). Conversion of 2-deoxy-L-arabino-hexose into 3 by modified, standard procedures, and on a large scale, gave a 75% yield.
Collapse
|
37
|
Lazzari E, Vigevani A, Arcamone F. Synthesis of some purine and pyrimidine nucleosides of 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranose (daunosamine). Carbohydr Res 1977; 56:35-42. [PMID: 880587 DOI: 10.1016/s0008-6215(00)84234-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The daunosaminyl analogue of the antibiotic puromycin and the nucleoside derivatives of daunosamine with adenine, thymine, and cytosine have been synthesised. The nucleoside derivatives of 6-dimethylaminopurine, thymine, and cytosine were prepared by melting the protected daunosamine with the protected base in vacuo. Daunosaminyladenine was obtained by condensing N-trifluoroacetyl-O-trifluoroacetyl-alpha-daunosaminyl chloride either with N6-benzoyl-9-chloromercuryadenine in boiling xylene or with N6-benzoyladenine in dichloromethane at room temperature in the presence of a molecular sieve. In each reaction, the beta-anomeric nucleoside was obtained, as shown by p.m.r. data. The protecting groups were removed with barium hydroxide or methanolic ammonia to give the free aminonucleosides in good yield. 9-beta-Daunosaminyl-6-dimethylaminopurine was coupled to N-benzylocyxcarbonyl-O-methyltyrosine, giving, after hydrogenolysis, the daunosaminyl analogue of puromycin.
Collapse
|
38
|
Lancini GC, Arioli V, Lazzari E, Bellani P. Synthesis and relationship between structure and activity of 2-nitroimidazole derivatives. J Med Chem 1969; 12:775-80. [PMID: 5812186 DOI: 10.1021/jm00305a012] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
39
|
Lancini GC, Lazzari E, Diena A. Synthesis of homologues of the antibiotic alanosine. Farmaco Sci 1969; 24:169-78. [PMID: 5768828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
40
|
Vertova F, Lazzari E. [Anatomical and radiological comparisons in myelography with iodated esters. Case studies]. Ann Radiol Diagn (Bologna) 1969; 42:13-29. [PMID: 5406588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
41
|
Lazzari E, Vertova F. [The disease of multiple exostoses. Correlations with other chondrodysplasias]. Boll Soc Med Chir Cremona 1968; 22:123-33. [PMID: 5306067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
42
|
|
43
|
Lancini GC, Lazzari E, Pallanza R. [Synthesis and anti-trichomonal activity of the methyl derivatives of azomycin]. Farmaco Sci 1966; 21:278-85. [PMID: 5935558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
44
|
|